| Ticker: EVTI | 1360 O'Brien Drive | |
| Exchange: NASDAQ-National Market | Menlo Park, California 94025 | |
| Industry: Manufacturing | (415) 325-1600 |
| Type of Shares: | Common Shares | Filing Date: | 12/19/95 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 2/7/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $24,000,000 | Selling: | $0.48 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,278,543 |
| Manager | Tier | Phone |
| Hambrecht & Quist Incorporated | Lead Manager | (415) 576-3423 |
| Montgomery Securities | Co-manager | 4156272220 |
| UBS Securities Inc. | Co-manager | (212) 230-4000 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/94 | 9/30/95 | 9/30/94 | 9/30/95 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $13.51 |
| Net Income: | -$7.88 | -$5.87 | -$5.65 | Liabilities: | $1.18 |
| EPS: | -$1.40 | -$0.94 | -$1.04 | Equity: | $12.33 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops and manufactures minimally invasive endovascular systems to repair diseased or damaged vascular structures. The Company's Endovascular Grafting System, or EGS systems, provides catheter-based delivery and implantation of a specialized sutureless prosthesis, or implant, to repair abdominal aortic aneurysms. The EGS system is currently in clinical trials in the United States, Europe and Australia. To the Company's knowledge, it is the only company to have received Investigational Device Exemption approval from the United States Food and Drug Administration to conduct human clinical trials in the United States with an endovascular system to treat AAAs. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for funding of clinical trials, expansion of facilities, research and development, working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.